NCEP-ATP III and IDF criteria for metabolic syndrome predict type 2 diabetes mellitus

Main Article Content

Eva Sulistiowati
Marice Sihombing



Subjects with metabolic syndrome (MetS) have a greater risk for acquiring type 2 diabetes mellitus (type 2 DM). The MetS criteria usually used are those of the National Cholesterol Education Program Expert Panel (NCEP) and Adult Treatment Panel III (ATP III) and of the International Diabetes Federation (IDF). This study aimed to evaluate the modified NCEP-ATP III and IDF criteria as predictor of type 2 DM among subjects with MetS.



A cohort study was conducted among 4240 subjects with MetS. MetS was determined according to the modified NCEP-ATP III and IDF criteria. The study followed up 3324 non-diabetic subjects of the cohort study of non-communicable disease (NCD) risk factors (NCD study) during a 2-year period. Type 2 DM was determined from the diagnosis by health personnel or from fasting blood glucose of ≥126 mg/dL or blood glucose of ≥200 mg/dL, 2 hours after 75g glucose loading.



The MetS prevalence based on modified NCEP ATP III and IDF criteria in non-DM subjects was 17.1% and 15.6%, respectively. The risk for DM in subjects with MetS using modified NCEP ATP III and IDF criteria was 4.7 (CI 95%: 3.4-6.5) and 4.1 (CI 95%: 3.0-5.7), respectively.



Both MetS criteria can be used as predictors of the occurrence of DM type 2, but the modified NCEP-ATP III is more properly applied than the IDF criteria in subjects with MetS. Screening programs and routine monitoring of MetS components are required for early detection of type 2 DM.

Article Details

How to Cite
Sulistiowati, E., & Sihombing, M. (2016). NCEP-ATP III and IDF criteria for metabolic syndrome predict type 2 diabetes mellitus. Universa Medicina, 35(1), 46–55.
Original Articles


Huang P. A comprehensive definition for metabolic syndrome. Dis Models Mech 2009; 2:231-7.

Deepa M, Farooq S, Datta M, et al. Prevalence of metabolic syndrome using WHO, ATP III and IDF definition in Asian Indians: the Chennai urban rural epidemiology study (CURES-34). Diabetes Metab Res Rev 2007;23:127-34.

Adams RJ, Appleton S, Wilson DH, et al. Population comparison of two clinical approaches to the metabolic syndrome. Diabetes Care 2005;28:2777-9.

Grundy MS, Cleemen JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005;112:2375-2.

Soewondo P, Purnamasari D, Oemardi M, et al. Prevalence of metabolic syndrome using NCEP/ATP III criteria in Jakarta, Indonesia: The Jakarta Primary Non-communicable Disease Risk Factors Surveillance 2006. Acta Med Indones-Indones J Intern Med 2010,42:199-203.

Pusparini. Central obesity, metabolic syndrome dan diabetes melitus tipe dua. Univ Med 2007;26:195-204.

Hanley AJG, Karter AJ, Willimas K, et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: The Insulin Resistance Atherosclerosis Study. Circulation 2005;112:3713-21.

Povel CM, Beulens JW, Van der Schouw YT, et al. Metabolic syndrome model definitions predicting type 2 diabetes and cardiovascular disease. Diabetes Care 2013;36:362-8.

Shin J A, Lee Jin-Hee, Lim Sun-Young, et al. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Invest 2013;4:334-43.

Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. The Lancet 2008;371:1927-35.

Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005;112:666-73.

Flato MO, Parush N, El-Hay T, et al. Predictive models for type 2 diabetes onset in middle-aged subjects with the metabolic syndrome. Diabetol Metab Syndr 2013;5:1-9.

Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes. Diabetes Care 2008;31:1898–904.

Julianty P, Riyadina W, Sirait A, dkk. Laporan Studi Kohor Faktor Risiko Penyakit Tidak Menular 2014. Badan Penelitian dan Pengembangan Kesehatan;2015.

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment panel III). National Heart, Lung, and Blood Institute. National Institutes of Health. NIH Publication 20002.No. 02-5215.

International Diabetes Federation. The IDF consensus worldwide definition of the Metabolic Syndrome. International Diabetes Federation; 2006.

American Diabetes Association. Diagnosis and classifcation of diabetes mellitus. Diabetes Care 2012;35:S69-S71.

Riyadina W, Musadad A, Rahajeng E, et al. Buku Pedoman Pemeriksaan Studi Kohor Risk factorsPTM. Badan Penelitian dan Pengembangan Kesehatan;2014.

Streiner DC, Norman GR. Health measurement seals. 2nd Ed. New York: Oxford University Press; 2000.

Cheung B, Nelson MS, Man YB, et al. Development of diabetes in Chinese with the metabolic syndrome. Diabetes Care 2007;30:1430–6.

Bhowmik B, Afsana F, Siddiquee T, et al. Comparison of the prevalence of metabolic syndrome and its association with diabetes and cardiovascular disease in the rural population of Bangladesh using the modified National Cholesterol Education Program Expert Panel Adult Treatment Panel III and International Diabetes Federation definitions. J Diabetes Invest 2015;6:280–8.

Moy F, Buigiba A. The modified NCEP ATP III criteria maybe better than the IDF criteria in diagnosing metabolic syndrome among Malays in Kuala Lumpur. BMC Public Health 2010;10:678. DOI: 10.1186/1471-2458-10-678.

Saukkonen T, Jokelainen J, Timonen M, et al. Prevalence of metabolic syndrome components among the elderly using three different definitions: a cohort study in Finland. Scand J Prim Health Care 2012; 30:29–34.

Dwipayana MP, Suastika K, Saraswati IMR, et al. Prevalensi Sindroma Metabolik pada Populasi Penduduk Bali, Indonesia. J Peny Dalam 2011;12:1-5.

Juutilainen A, Kortelainen S, Lehto S, et al. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 2004;27:2898-904.

Rohman. Patogenesis dan terapi metabolic syndrome. J Kardiol Ind 2007;28:160-8.

Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes and CVD? Arterioscler Thromb Vac Bio 2004;24:816-23.

Chackrewarthy S, Gunasekera D, Pathmeswaren A, et al. A comparison between revised NCEP ATP III and IDF definitions in diagnosing metabolic syndrome in an Urban Sri Lankan population: the Ragama Health Study. ISRN Endocrinol 2013; Article ID 320176,7 pages.

Wilson P, D’Agostino R, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066-72.